DBVT
DBV TechnologiesDBVT
DBVT
About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Employees: 109
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
14.01% less ownership
Funds ownership: 16.67% [Q3] → 2.66% (-14.01%) [Q4]
25% less capital invested
Capital invested by funds: $11.3M [Q3] → $8.46M (-$2.8M) [Q4]
25% less funds holding
Funds holding: 24 [Q3] → 18 (-6) [Q4]
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
92% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
11%
upside
Avg. target
$10
11%
upside
High target
$10
11%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets Jonathan Wolleben 49% 1-year accuracy 33 / 68 met price target | 11%upside $10 | Market Outperform Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 4 articles about DBVT published over the past 30 days
Neutral
GlobeNewsWire
6 hours ago
DBV Technologies Reports First Quarter 2025 Financial Results
Châtillon, France, April 30, 2025 DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025.
Positive
Zacks Investment Research
12 hours ago
Here's Why Momentum in DBV Technologies (DBVT) Should Keep going
DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Neutral
GlobeNewsWire
2 weeks ago
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced: The audited financial statements for the year ended December 31, 2024 were approved by the Board of Directors on April 11, 2025, and present no changes from the unaudited financial statements examined by the Board of Directors on March 23 and published in the Company's press release dated March 24, 2025; The filing, for the year ended December 31, 2024, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the 2024 URD includes the following information: The Annual Financial Report; The Management Report (“rapport de gestion”); The Corporate Governance Report; The description of the Share Buyback Program.
Negative
MarketBeat
2 weeks ago
3 Biopharmaceutical Stocks Bucking the Sell-Off
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.
Positive
Market Watch
1 month ago
DBV Technologies ADRs Rise After Up to $306.9M in New Financing
American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.
Neutral
GlobeNewsWire
1 month ago
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants DBV sufficiently funded through the expected Biologics License Application (BLA) submission to Food and Drug Administration (FDA) for the Viaskin® peanut patch in children 4 – 7-years-old and commercial launch, if approved DBV will host an investor conference call on Monday, March 31 st at 5:00pm ET (23h00 CET) to discuss the financing and FDA update DBV Technologies (the “Company” or “DBV”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT), a clinical-stage biopharmaceutical company dedicated to treating pediatric allergies, today announced a financing of up to $306.9 million (€284.5 million), including gross proceeds of $125.5 million (€116.3 million) to be received upon closing and an aggregate of up to ($181.4 million) (€168.2 million) in gross proceeds if all the warrants are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warrants.
Neutral
GlobeNewsWire
1 month ago
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results
Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results 1 COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension (OLE) are sufficient to support a Biologics License Application (BLA) for Viaskin peanut patch in children 4 – 7-years-old VITESSE topline results on-track for the fourth quarter of 2025 BLA submission for Viaskin peanut patch in children 4 – 7-years-old is now expected in the first half of 2026; DBV anticipates this path may accelerate potential launch, if approved by the FDA, by approximately one year DBV also reports unaudited financial results 1 for the full year 2024, including cash and cash equivalents DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT, the “Company”), a clinical-stage biopharmaceutical company, today announced that in a Written Responses Only to the Company's Type D IND meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company's proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a Biologics License Application (BLA) filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required, which accelerates the timeline for a BLA submission of Viaskin® peanut patch in 4 – 7-year-olds with a peanut allergy.
Neutral
GlobeNewsWire
2 months ago
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Professor of Pediatrics at Children's Hospital Colorado, will describe Month 60 (M60), end-of-study efficacy and safety results from PEOPLE (the open-label extension of the 12-month, double-blind placebo-controlled, Phase 3 PEPITES study in peanut allergic children aged 4-11 years).
Neutral
GlobeNewsWire
3 months ago
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated Information Châtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024: 266,868 DBV Technologies shares, € 106,930.51.
Positive
Benzinga
4 months ago
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
On Wednesday, DBV Technologies SA DBVT reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years.
Charts implemented using Lightweight Charts™